Vice President, Medical Affairs Oncology

About Parabilis Medicines Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP) and a range of other solid tumor indications. Beyond zolucatetide, Parabilis is advancing additional Helicon-based programs focused on other challenging targets where we believe our medicines could have life-altering impact. For more information, visit www.parabilismed.com or follow us on LinkedIn . What’s the opportunity? The Vice President, Medical Affairs Oncology is a member of the Development Leadership Team reporting to the Chief Medical Officer. This senior executive leader is accountable for the end-to-end design and execution of the Medical Affairs strategy across Parabilis portfolio, including Scientific Communications, Medical Education, Evidence Generation, Key Opinion Leader (KOL) Engagement, Publication Planning, and Medical Information. This role ensures scientific excellence and cross-functional integration across all development programs and builds a scalable Medical Affairs organization capable of supporting global, multi-indication growth. Key Responsibilities: Strategic Leadership Define and execute the Medical Affairs Oncology strategy aligned with the clinical development roadmap and portfolio priorities. Serve as a core member of the Development Leadership Team and contribute to broader Development governance and portfolio decision-making. Support portfolio-level medical prioritization, lifecycle planning, and cross-indication strategy. KOL Engagement & Medical Education Build and sustain relationships with leading KOLs, academic medical centers, and cooperative groups relevant to Parabilis’ pipeline. Design and oversee Medical Education programs that advance understanding of Parabilis’ science, novel mechanisms, and unmet need across tumor types. Evidence Generation & Publication Strategy Lead the development and execution of a robust evidence generation strategy, including investigator-initiated studies, real-world evidence, and health outcomes research Oversee development and execution of a comprehensive publication plan aligned with clinical milestones and regulatory timelines Build global medical affairs infrastructure to support multi-program, multi-regional growth Drive Medical Affairs KPIs and impact metrics in support of portfolio strategy and commercial readiness Scientific Communications & Medical Information Lead scientific communications strategy to accurately and compellingly convey the differentiated profile of Parabilis’ Helicon™ platform and pipeline assets Oversee Medical Information function, ensuring timely, accurate, and compliant responses to healthcare professional inquiries Oversee the creation of high-quality medical education materials, slide decks, and scientific exchange resources Establish scalable medical affairs infrastructure to support launch readiness across tumor types and geographies Patient Advocacy and Patient Support Building trusted partnerships with advocacy organizations across Parabilis' specific tumor types Integrating the patient voice into MA strategy, trial design, and evidence generation Collaborating with patient communities on disease awareness and education Developing patient support programs to improve access, adherence, and trial participation ensuri